These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8264906)

  • 21. SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.
    Tatsch K; Schwarz J; Oertel WH; Kirsch CM
    Nucl Med Commun; 1991 Aug; 12(8):699-707. PubMed ID: 1838142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alterations of striatal dopamine D2 receptors contribute to deteriorated response to L-dopa in Parkinson's disease: a [123I]-IBZM SPET study.
    Pizzolato G; Chierichetti F; Rossato A; Cagnin A; Fabbri M; Dam M; Ferlin G; Battistin L
    J Neural Transm Suppl; 1995; 45():113-22. PubMed ID: 8748616
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD; Abrams DN; Greenberg CR; Hobson D
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease.
    Seppi K; Schocke MF; Donnemiller E; Esterhammer R; Kremser C; Scherfler C; Diem A; Jaschke W; Wenning GK; Poewe W
    Mov Disord; 2004 Dec; 19(12):1438-45. PubMed ID: 15390073
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.
    Schwarz J; Tatsch K; Vogl T; Kirsch CM; Trenkwalder C; Arnold G; Gasser T; Oertel WH
    Mov Disord; 1992; 7(1):58-61. PubMed ID: 1532631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical impact of cerebral dopamine-D2 receptor scintigraphy].
    Larisch R; Klimke A
    Nuklearmedizin; 1998; 37(7):245-50. PubMed ID: 9830615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparison of D2 receptor scintigraphy (123I-IBZM) with cerebral perfusion (99m-Tc-HMPAO) in extrapyramidal disorders].
    Saur HB; Bartenstein P; Schober O; Oberwittler C; Lerch H; Masur H
    Nuklearmedizin; 1994 Oct; 33(5):184-8. PubMed ID: 7997375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative quantification of signal on T2-weighted images in the basal ganglia: limited value in differential diagnosis of patients with parkinsonism.
    Schwarz J; Kraft E; Vogl T; Arnold G; Tatsch K; Oertel WH
    Neuroradiology; 1999 Feb; 41(2):124-8. PubMed ID: 10090605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine D2 receptor brain imaging in the neonatal period using 123I-IBZM SPECT.
    Tranquart F; Saliba E; Zimmer L; Barantin L; Lanneau M; Guilloteau D; Baulieu JL
    J Nucl Med; 1999 Dec; 40(12):2126-7. PubMed ID: 10616897
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI.
    Arnold G; Tatsch K; Oertel WH; Vogl T; Schwarz J; Kraft E; Kirsch CM
    J Neural Transm Suppl; 1994; 42():111-8. PubMed ID: 7964681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.
    Jauss M; Krack P; Franz M; Klett R; Bauer R; Gallhofer B; Dorndorf W
    Mov Disord; 1996 Nov; 11(6):726-8. PubMed ID: 8914102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
    Volk S; Maul FD; Hör G; Schreiner M; Weppner M; Holzmann T; Pflug B
    Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy.
    Hertel A; Weppner M; Baas H; Schreiner M; Maul FD; Baum RP; Fischer PA; Hör G
    Nucl Med Commun; 1997 Sep; 18(9):811-22. PubMed ID: 9352546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No direct correlation between behaviorally active doses of the dopamine D2 agonist LY 171555 and displacement of [123I]IBZM as measured with SPECT in MPTP monkeys.
    Vermeulen RJ; Drukarch B; Verhoeff NP; Goosen C; Sahadat MC; Wolters EC; van Royen EA; Stoof JC
    Synapse; 1994 Jun; 17(2):115-24. PubMed ID: 7916490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C; Toska K; Friberg L; Holm S; Angelo HR; Knudsen GM
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. D2 receptor imaging with iodine-123-iodobenzamide brain SPECT in infants with hypoxic-ischemic brain injury.
    Kapucu LO; Koç E; Gücüyener K; Zenciroğlu A; Atalay Y; Unlü M; van Royen E
    J Nucl Med; 1998 Oct; 39(10):1703-7. PubMed ID: 9776272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW; Reijs AE; de Swart J; Kaandorp Y; Lamberts SW; Krenning EP; Kwekkeboom DJ
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis.
    Hierholzer J; Cordes M; Schelosky L; Richter W; Keske U; Venz S; Semmler W; Poewe W; Felix R
    J Nucl Med; 1994 Dec; 35(12):1921-7. PubMed ID: 7989970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease.
    Ichise M; Toyama H; Fornazzari L; Ballinger JR; Kirsh JC
    J Nucl Med; 1993 Aug; 34(8):1274-81. PubMed ID: 8326384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide.
    Nadeau SE; Couch MW; Devane CL; Shukla SS
    J Nucl Med; 1995 Mar; 36(3):384-93. PubMed ID: 7884499
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.